Cancer researchers and drug companies may have been too quick to ignore a promising line of inquiry that targets a specific cell protein, according to a research team.
Cancer researchers and drug companies may have been too quick to ignore a promising line of inquiry that targets a specific cell protein, according to a research team.
Share this Article
Recommended